Prognostic Evaluation
Prognostic Evaluation - Related Videos
05:16
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
0 Views •
Cited by 1 •
2025
This protocol presents R codes for performing restricted cubic spline multivariable Cox regression analysis to determine the cutoff value of the phase angle for prognosis in acute heart failure as well as codes for calculating statistics that measure the discriminatory ability of each model and evaluate its goodness of fit.
08:45
Evaluation of 3D Spheroids for AAV Transduction Studies
0 Views •
2026
Three-dimensional spheroid culture systems improve upon conventional 2D models for AAV gene therapy development. This methodology enables sensitive detection of AAV transduction at low doses, enhanced physiological relevance, and robust long-term monitoring. The platform supports potency assessment, high-throughput screening, and vector optimization across diverse cell lines and AAV serotypes.
07:25
Ultrasonographic Evaluation of Salivary Glands for Sjogren's Syndrome: Diagnostic and Monitoring Insights
0 Views •
Cited by 1 •
2023
Salivary gland ultrasonography is a promising tool for the diagnosis and evaluation of disease activity and complications in Sjogren's syndrome (SS). The scanning technique for salivary gland ultrasound examination relevant to SS is described in the article.
08:08
Cell-based Assay Protocol for the Prognostic Prediction of Idiopathic Scoliosis Using Cellular Dielectric Spectroscopy
0 Views •
Cited by 8 •
2013
A structured protocol is presented for a cell-based assay as a functional test to predict the prognosis of idiopathic scoliosis using cellular dielectric spectroscopy (CDS). The assay can be performed with fresh or frozen peripheral blood mononuclear cells (PBMCs) and the procedure is completed within 4 days.
06:03
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
0 Views •
Cited by 42 •
2020
Breast cancer related lymphedema is frequent in breast cancer survivors, but there are not widely employed guidelines for its diagnosis and quantification. Here, we introduce a reliable and cost-effective protocol to define, quantify, and compare upper limb volume in breast cancer patients.
FAQs
Discrimination indicates how effectively a model separates people with different future outcomes, whereas calibration examines whether predicted risks correspond to what is actually observed. A model may distinguish higher- and lower-risk individuals yet systematically overestimate or underestimate their risks. Considering both properties gives a more complete statistical assessment and prevents reliance on a single performance perspective.
Time-to-event analysis incorporates when an outcome occurs rather than considering only whether it occurred. This is especially relevant when prognosis concerns survival or disease progression, because individuals may experience outcomes at different times. Using this perspective allows evaluation to reflect the timing of predicted and observed outcomes, supporting more informative interpretation of longitudinal biomedical data.
The biomarker should be assessed alongside established clinical factors rather than evaluated in isolation. Prognostic evaluation can then examine whether its inclusion improves the model's ability to distinguish risks or align predicted risks with observed outcomes. This comparison clarifies whether the candidate predictor contributes useful information for risk stratification or merely duplicates what existing factors already provide.
Validation tests whether observed performance remains reliable beyond the data used to develop or assess the model. When results are examined in new data, investigators can identify whether apparent predictive ability is consistent or may reflect limitations of the original dataset. This step strengthens interpretation by addressing uncertainty and highlighting potential bias before broader application.
A practical evaluation begins by comparing predicted risks with observed outcomes, then selecting performance measures suited to the prognostic question. Investigators assess discrimination, calibration, and, when outcomes unfold over time, time-to-event behavior. They subsequently examine performance in new data and interpret uncertainty, bias, and limitations before deciding whether the findings support further use.
Its results can guide risk stratification by indicating how confidently individuals may be assigned to different prognostic groups. The findings also inform study design and help judge whether a candidate model or biomarker offers evidence relevant to treatment response, disease progression, or survival. Careful interpretation is essential because uncertainty, bias, and performance limitations affect how results should be applied.